ADAGIO THERAPEUTICS Funding & Investors

Waltham, MA

Adagio Therapeutics is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1, and additional potentially emergent coronaviruses. They believe that antibodies will match or exceed the potency and coverage of conventional SARS-CoV-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. Their candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. Their portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape.